Shop By
Catalog No.
Product Name
Application
Product Information
Product Citation
-
PPARγ agonist
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. -
PPAR agonist
Rosiglitazone works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. -
PPAR agonist
Rosiglitazone maleate, an antidiabetic drug, works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.- Camilla Bean, .et al. , Nat Metab, 2021, Dec;3(12):1633-1647 PMID: 34873337
-
PPARγ agonist
Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. -
PPARγ agonist
Troglitazone is a selective PPARγ receptor agonist (EC50 values are 780 and 555 nM at murine and human PPARγ receptors respectively).- Julien Allard, .et al. , Cell Biol Toxicol, 2020, Jun 14 PMID: 32535746
-
PPAR-α/γ agonist
Aleglitazar is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. -
PPARα/γ dual agonist
Chiglitazar is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively. -
PPARδ agonist
Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1. -
PPAR-γ partial agonist
Balaglitazone is a novel partial agonist of PPAR-gamma (γ). -
PPARγ agonist
Inolitazone dihydrochloride is a novel high-affinity PPARγ agonist, which activates PPARγ with an EC50 about 1/50 that of rosiglitazone and has no effect on RIE cells. -
PPAR agonist
Elafibranor is an agonist of the peroxisome proliferator-activated Receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.- Joost Boeckmans, .et al. , Cells, 2022, 11(5), 893 PMID: 35269515
- Tomasz Kostrzewski, .et al. , Commun Biol, 2021, 4: 1080 PMID: 34526653
- Joost Boeckmans, .et al. , MethodsX, 2020, 7: 101068 PMID: 33024711
- Joost Boeckmans, .et al. , Cell Biol Toxicol, 2020, Jul 1 PMID: 32613381
- Joost Boeckmans, .et al. , Data in Brief, 2019, June 3 PMID: 31294056
- Boeckmans J, .et al. , Pharmacol Res, 2019, Apr 24. pii: S1043-6618(18)31850-4 PMID: 31028903
-
PPAR agonist
BMS-687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) alpha agonist, with an EC(50) of 10 nM for human PPARalpha and approximately 410-fold selectivity vs human PPARgamma in PPAR-GAL4 transactivation assays. -
PPAR agonist
Bezafibrate is the first clinically tested dual and pan-PPAR co-agonist. -
PPARγ agonist
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. -
PPAR agonist
Etofylline, also known as BRN-0251760, is a peroxisome proliferator-activated receptor (PPAR) agonist used to treat respiratory and cardiovascular disorders. Etofylline is often used as a bronchodilator. -
PPAR gamma agonist
Leriglitazone is a peroxisome proliferator activated receptor (PPAR) gamma agonist. -
PPAR-δ agonist
Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases. -
PPAR-α agonist
Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis. -
PPARδ agonist
PPARδ agonist is a PPARδ agonist extracted from patent US20180071304, compound example 10. -
PPAR agonist
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. -
PPAR-δ agonist
Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC50 2 nM), and specific PPAR-δ agonist. -
PPARδ agonist
Fonadelpar is a PPARδ agonist, used in the research of neuroparalytic keratopathy. -
PPAR alpha/gamma agonist
Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC50s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively. -
PPARγ agonist
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes. -
PPAR agonist
Indeglitazar is an orally available peroxisome proliferator-activated receptor (PPAR) pan-agonist for all three PPAR subtypes alpha (α), delta (δ) and gamma (γ). -
PPARγ agonist
Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition. -
PPAR alpha agonist
Pemafibrate, also known as (R)-K 13675, is a PPAR alpha agonist. -
PPARγ agonist
Sipoglitazar, also known as TAK-654, is a PPARγ agonist potentially for the treatment of diabetes.